Tracy Lab Research
Laboratory for Clinical Biochemistry Research (LCBR)
The molecular, cellular and genetic epidemiology of coagulation, fibrinolysis, and inflammation with emphasis on innate and adaptive immunity: all studied with respect to the etiology of atherosclerosis and coronary heart disease, other chronic complex diseases of aging, and the process of aging itself. Laboratory for Clinical Biochemistry Research direct web page
Research program development and organization; research-related resource allocation; and faculty recruitment and development.
Dr. Tracy’s approach to research reflects his training in biochemistry and clinical chemistry, and his long interest in population-based science. Areas of research include the interrelationships of coagulation, fibrinolysis and inflammation, especially the innate and adaptive immune systems, in the etiology of atherosclerosis and coronary heart disease, insulin resistance and diabetes, HIV-related morbidity and mortality, and other complex diseases, as well as more broadly in the process of aging. The main tools of the laboratory are those of molecular and genetic epidemiology, in the context of multi-center studies and clinical research. More basic biochemical approaches are used in the development of new assays for epidemiological application. He has a long standing interest in disease risk modeling and risk assessment as well as in developing new biomarkers for clinical and epidemiological research. He also collaborates on studies of murine models of atherosclerosis with Dr. Sally Huber of the Pathology Department.